<SEC-DOCUMENT>0001193125-25-122482.txt : 20250519
<SEC-HEADER>0001193125-25-122482.hdr.sgml : 20250519
<ACCEPTANCE-DATETIME>20250519163017
ACCESSION NUMBER:		0001193125-25-122482
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250519
DATE AS OF CHANGE:		20250519

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYNAVAX TECHNOLOGIES CORP
		CENTRAL INDEX KEY:			0001029142
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				330728374
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34207
		FILM NUMBER:		25964430

	BUSINESS ADDRESS:	
		STREET 1:		2100 POWELL STREET
		STREET 2:		SUITE 720
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		5108485100

	MAIL ADDRESS:	
		STREET 1:		2100 POWELL STREET
		STREET 2:		SUITE 720
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d934443ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROXY
STATEMENT PURSUANT TO SECTION 14(a) OF THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the Registrant&#8194;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other
than the Registrant&#8194;&#9744; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material Pursuant to <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Dynavax Technologies Corporation </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement if other than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rule
<FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11.</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Schedule 14A filing consists of the following letter distributed by Dynavax Technologies Corporation
(the &#147;Company&#148;) to its stockholders in connection with the Company&#146;s 2025 Annual Meeting of Stockholders. The letter was first used or made available on May&nbsp;19, 2025. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VOTE TODAY AND PROTECT THE VALUE OF YOUR INVESTMENT IN DYNAVAX! </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is a critical moment for Dynavax &#150; one that requires you to make an important decision that will affect the future value of your investment in the
Company. The Dynavax Board of Directors is singularly focused on enhancing long-term value for all stockholders. We have the right Board, are successfully executing the right strategy and are delivering record financial and operational results. We
have <B>delivered returns of 203% to stockholders over the last five years</B> (as of April&nbsp;17, 2025, the date Dynavax filed its definitive proxy), far outperforming vaccine peers, which have returned 9%, and the S&amp;P Biotechnology Select
Industry Index, which has declined 17% and <B>Dynavax is one of the few vaccine companies that has returned meaningful capital to stockholders</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each
of Dynavax&#146;s four director nominees &#151; Brent MacGregor, Scott Myers (our Chairman), Lauren Silvernail<B> </B>and<B> </B>Elaine Sun &#151; is essential to our Board. They bring expertise across the biotechnology and vaccine space for Dynavax
and have led multiple strategic transactions generating billions of dollars in value and maximizing stockholder value. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g934443g0519042710253.jpg" ALT="LOGO" STYLE="width:3.61528in;height:1.5375in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Do not let Deep Track derail Dynavax&#146;s positive trajectory by replacing these four critical members of our Board with
inferior candidates. Deep Track is entirely focused on implementing its <FONT STYLE="white-space:nowrap">one-dimensional</FONT> plan to strip-mine Dynavax that will jeopardize long-term stockholder value. <B>We strongly urge you to vote
&#147;FOR&#148; all four of Dynavax&#146;s nominees on the </B><B><U>GOLD</U></B><B> proxy card today. </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With our June&nbsp;11 Annual Meeting fast
approaching, it is extremely important that you vote as soon as possible, no matter how many shares you own. Voting is quick and easy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By mail: Complete,
sign, date and return the <B><U>GOLD</U></B> proxy card or <B><U>GOLD</U></B> voting instruction form in the postage-paid envelope provided. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By internet:
The <B><U>GOLD</U></B> proxy card or <B><U>GOLD</U></B> voting instruction form received includes a URL to submit votes electronically. Follow the instructions on the voting website and submit your vote by 8:59 p.m. PT on June 10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By <FONT STYLE="white-space:nowrap">e-mail:</FONT> If you received proxy materials via <FONT STYLE="white-space:nowrap">e-mail,</FONT> the <FONT
STYLE="white-space:nowrap">e-mail</FONT> message included a link with instructions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Remember &#150; please disregard Deep Track&#146;s proxy materials
and only vote on Dynavax&#146;s <B><U>GOLD</U></B> proxy card. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you have questions about how to vote your shares, please call the firm assisting us
with the solicitation of proxies, MacKenzie Partners, at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-322-2885.</FONT></FONT></FONT> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication contains &#147;forward-looking&#148; statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, and
Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, which are subject to a number of risks and uncertainties. All statements that are not historical facts are forward-looking statements. Forward-looking statements can generally be
identified by the use of words such as &#147;expect,&#148; &#147;will,&#148; &#147;potential,&#148; and similar expressions, or the negatives thereof, or they may use future dates. Forward-looking statements made in this document include statements
regarding expected contributions from our current directors, expectations regarding delivering value for our stockholders, our future growth, our business strategy and long-term performance. Actual results may differ materially from those set forth
in this communication due to the risks and uncertainties inherent in our business, including, the risk that circumstances surrounding or leading up to our 2025 Annual Meeting may change, risks relating to our ability to commercialize and supply <FONT
STYLE="white-space:nowrap">HEPLISAV-B,</FONT> the risks that market size or actual demand for our products may differ from our expectations, risks related to the timing of completion and results of current clinical studies, risks related to the
development and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical testing of vaccines containing CpG 1018 adjuvant, and risks related to the implementation of our long-term growth objectives, as well as other risks detailed in the
&#147;Risk Factors&#148; section of our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the three months ended March&nbsp;31, 2025 and any periodic filings made thereafter, as well as discussions of potential risks,
uncertainties and other important factors in our other filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made as of the date hereof, are qualified in their entirety by this cautionary statement and we
undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Information on Dynavax&#146;s website at www.dynavax.com is not incorporated by reference in
our current periodic reports with the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Additional Information and Where to Find It </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On&nbsp;April 17, 2025, the Company filed a definitive proxy statement on Schedule 14A (the &#147;Proxy Statement&#148;) and form of accompanying GOLD proxy
card with the&nbsp;U.S. Securities and Exchange Commission&nbsp;(the &#147;SEC&#148;) in connection with its 2025 Annual Meeting and its solicitation of proxies for the Company&#146;s director nominees and for other matters to be voted on. The
Company may also file other relevant documents with the&nbsp;SEC&nbsp;regarding its solicitation of proxies for the 2025 Annual Meeting. This communication is not a substitute for any proxy statement or other document that the Company has filed or
may file with the&nbsp;SEC&nbsp;in connection with any solicitation by the Company. STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT, ACCOMPANYING GOLD PROXY CARD AND OTHER RELEVANT DOCUMENTS FILED WITH, OR FURNISHED
TO, THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION. Stockholders may obtain a copy of the Proxy Statement, accompanying GOLD proxy card, any amendments or supplements to the Proxy Statement and any other relevant
documents filed by the Company with the&nbsp;SEC&nbsp;at no charge at the&nbsp;SEC&#146;s&nbsp;website at&nbsp;www.sec.gov. Copies will also be available at no charge at the Company&#146;s website
<FONT STYLE="white-space:nowrap">at&nbsp;https://investors.dynavax.com/sec-filings.</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Information Regarding Participants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication is neither a solicitation of a proxy or consent nor a substitute for any proxy statement or other filings that may be made with
the&nbsp;SEC. The Company, its directors, its director nominees and certain of its executive officers and employees may be deemed to be participants in the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
solicitation of proxies for the 2025 Annual Meeting. Information regarding the names of such persons and their respective direct or indirect interests in the Company, by securities holdings or
otherwise, is available in the Proxy Statement, which was filed with the&nbsp;SEC&nbsp;on&nbsp;April 17, 2025, including in the sections captioned &#147;Compensation Discussion and Analysis,&#148; &#147;Summary Compensation Table,&#148; &#147;Grants
of Plan Based Awards,&#148; &#147;Outstanding Equity Awards at Fiscal Year End,&#148; &#147;Pay Ratio Disclosure,&#148; &#147;Director Compensation,&#148; &#147;Certain Transactions,&#148; &#147;Security Ownership of Certain Beneficial Owners and
Management,&#148; and &#147;Supplemental Information Regarding Participants in the Solicitation.&#148; To the extent that the Company&#146;s directors and executive officers have acquired or disposed of securities holdings since the applicable
&#147;as of&#148; date disclosed in the Proxy Statement, such transactions have been or will be reflected on Statements of Changes in Ownership of Securities on Form 4 or Initial Statements of Beneficial Ownership of Securities on Form 3 filed with
the&nbsp;SEC. These documents are or will be available free of charge at the&nbsp;SEC&#146;s&nbsp;website at&nbsp;www.sec.gov. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g934443g0519042710253.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g934443g0519042710253.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "1 58# 2(  A$! Q$!_\0
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MV^%1G'W=N#GYCUZ8ZGTJ$7.MM>EELD3<%5MRC"\GOG+8!![?SI@,N-5@N!)
M=+F=@GS[?E( #,1GZKQZY%/36(;38ATF6-]VP+&NXX4%0<X]L?0BI(]6U"5K
MM%M$,L,881C)PV?NYSSQSVJ/^U-5-VMJMK&)3DL'&=BY&&.#Z$\>W6D O]L6
ML/FJ=-*QJNYGC4%&)7=QZY( ![FH1?P2S^?=:;MD1&P"25]P!CEN>>.*G2YU
MP7#2O;?NF  3 .SGKP<MQVXI7OM<D2;RK!(]NX(7&2?0XW?7OS0 EKK"7)D>
M73G!$+2)^[^8J /E^O)]J8-<A!4C2)LL%^8(N#DGC/\ G[R^M6[B\U5+IT@L
M4DB&S:Y."P.-Q_#YN/8>O%6/5-:FB22+3D970L&.5YQD#&?U[^U #GUF&)/W
M6GCS6;<B]/[V22!P1CGTW#UH75XBL$3:5)RX7 C 52>XS['/YU)]KUP3M%]C
MB(!P)3G!&[&<9].V<U)'>ZJTT"M8*JN^)<G_ %8X[]^,G/MCWH B@N;=M2F@
M?356261D=P-VX#.#R.F%&?3(ZYJ.378!%N.FR,^?W:!0=QZX!]1GGT)-6H+[
M4GOVCDL"EN'<!^Y '!ZXY/'Y4B7VJ-:QR-IV)&9PR9Y4#E3C/<#'7J1VH JW
M.I&'4Y();")HEC SMZ9"]3V7L3C''X4K:S!+*P&ER,54;FD0#:N,\Y'8_P"-
M317^K/&AEL1$Q(W *6P,'GKZ\8[=>:1+S6P80]A&0[ ,V[[@S@Y_GGM0!<TJ
MX6\M?M1CC29R0^P>AXR?I@_C67K7_(W>&?\ KI<_^B3718'IUKG=:_Y&[PS_
M -=+G_T2:J&_W_D3+8Z*BBBI*"N1TO6=+T[Q#XEBOM2L[61KY&"3SJA(\B+G
M!/2NNJE>PZ9%%->7T5HL<:EY9ID7"J!U)/:JBTKW$T^A6_X2GP]_T'M+_P#
MR/\ QH_X2GP]_P!![2__  ,C_P :S&UKPT0AALXIEDY1UMAAQ[$CG\*M6MWH
M5T5 T]$W="]I\I_'&*/=%[Q9_P"$I\/?]![2_P#P,C_QH_X2GP]_T'M+_P#
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MW_0>TO\ \#(_\:=LT'^YIOY)1LT'^YIOY)1[2EW_ !"[&_\ "4^'O^@]I?\
MX&1_XU2\!LK^"]/=&#*WF$$'((\QJT4AT21PB1:>S'H J$FM".-(HPD:*B+T
M51@"J4XN-H@D[W'4444B@KG/'$B0^&3)*ZI&EW:LS,<!0)X\DFNCIDD4<T9C
ME170]589!_"G%V:8FKJQF?\ "4^'O^@]I?\ X&1_XT?\)3X>_P"@]I?_ (&1
M_P"-87BCQ=X+\(R+;ZD+9KU@"MG;VXDF.>GR@<?CBN;'Q8\)JCS3>&[N.W3&
MZ3[-"V,]. WMTIW@"4F>@_\ "4^'O^@]I?\ X&1_XT?\)3X>_P"@]I?_ (&1
M_P"-9FA>(/!GB2S^U:7<:;,@^^C(J.A_VE8 C\JU-N@_W=-_)*EU*2=FQ78G
M_"4^'O\ H.Z7_P"!D?\ C1_PE/A[_H.Z7_X&1_XTNW0?[NF_DE&W0?[NF_DE
M+VM+O^*"[$_X2GP]_P!![2__  ,C_P :R;CQ' UU*8/$^B+#O4H&N8_N]QUZ
M]?TK7VZ#_=TW\DHVZ#_=TW\DH]K2[_B@NS%C\21I&ID\2:-(X .!>1*#SR#]
M1T/;OFFQ:]''N_XJK1BS=2]Y&P!Y/ XXS@8],^@K<VZ#_=TW\DHVZ#_=TW\D
MH]K2[_B@NRM8^)]'6SC%WXATIY^=Q%W'Z\=_2K'_  E/A[_H/:7_ .!D?^-+
MMT'^[IOY)1MT'^[IOY)1[6EW_%"NQ/\ A*?#W_0>TO\ \#(_\:/^$I\/?]![
M2_\ P,C_ ,:7;H/]W3?R2C;H/]W3?R2CVM+O^*'=B?\ "4^'O^@]I?\ X&1_
MXT?\)3X>_P"@]I?_ (&1_P"-+MT'^[IOY)1MT'^[IOY)1[6EW_%!=B?\)3X>
M_P"@]I?_ (&1_P"-8][J^F:EXQ\-I8ZC:73(]P66"=7('E'DX-;.W0?[NF_D
ME6K6WT_(FM(;7(X#Q*O\Q51J4[^ZQ:LMT444BPKC=?UM)8;Y)MATZ.-UE1E!
M#J =V?K7829\I]OWMIQ7B7C+419>$KA68 W#"(Y]#R?Y5+>J1<8W391T7PU-
MX]O)-5U:[GBL;(K%:V\38 ('W0>P (![DFHM.U:Z\$>-AX<OKR]FT74#NM-L
MV#%+G@#V)X(]P?6M/P8 _@2TNTU":.%Q+([+(%V,6.0,C!.1W/3/M7$_%,6U
MI;:;=12,UT[+)$^XG;CDX]LUBJG[PZI4K4;GL.L1YN3*L:C 'FD=R3@&JL5E
M//$)8XP4+[ 2P&6XX&3SU%7KBYCN="FN@<M-9Q2?B2I%16VH2VUEY0@WH)?,
M#;B.1CKCMP*\?,:%*%>[T35_F>5-)2*?D2>8Z%0&3.X$CMU^M1[?]D\<]*UV
MUFXV(OV1!]XCK_%1_;MT6D8VZ,SJ5)()(Y8_INQCV%<'LZ/\WX$V1FFUF%LM
MP8\1,<*V1S]!UJ+:<9VG\JT;;49K2UCC6V5E!)W.2<CH<?W>O45)+JEU/"\'
MV=42567&3CHO//H%_4TO9TN6Z>O:PK(RL#THP/2GM%(IPR,#]*38^W=L;:>^
M*PLQ#<#THP/2@@CJ"** # ]*,#THHH ,#THP/2BB@ KTS3I&ETRUD<Y9HE)/
MJ<5YGVKTG2O^019_]<5_E7L9/\<O0UI;ERBBBO?-PKA_BIXV;P/X/DN[;:=1
MN7\BT##(5B"2Y'HH&?KBNXKY]_:6\]KGPV@#&(K<$ =VS'_3% 'D.AF75_$L
M)OIYI9KZ?9+.6+288_.V?7&>?>OHV6V\.7/A/^Q+/1W^QW :$>7:MPP'#%NO
M<?-7SIHD=Q8S6E\H9'CE5HST)Y[?E7NH\56QTR34I/% ";=QMTP)0V.0%ZY[
M<\8YKEK-W.W#Q36IX.9]2\*ZY%<PL8+R!BD@[,5."#Z@C%>_Z#J,?B#2[.^M
M$_X^E&$SRK="OX'BOG[6;N74YKBXDC;<S>:<_P .3S7K7P?FFC\,1N%W&*\)
MC4]^AQ^=<69THRIQJ2W3M\CSZ\5NCM2A5BI4Y!P>.])M/]T_E6M%J\L(=(+*
M-,OYQRS'D$-GGZ4#6[A3&$ME5$.-F6(/R[<?UKQ_9TNLOP.>R[F3C R1QZXJ
MT-,N_,2/R0'?&%+*#STXS[U8GU2YNX'MS"-LN>!GJ6W9_IFI(M8G4QA+125"
M@9W$G!!')YQQTHC"C?63^X=D9.T_W3^5&TXSM./I6Q!J]Y$D3BWC=53:2>K=
M &/_ 'R!^%,36KM"%$61M5=O.,*".GOGGZ4>SI:>\_N%9&?!:RW+[(D!;C )
M SGIUJ+ ]*U_[;N$:/\ T1%\H!<?-V(/\Q6145(TXI<KN#MT# ]*,#THHK(0
M8'I1@>E%% !@>E=!X0D9=3EC!.QHB2.V01@_K7/UO>$?^0P__7$_S%=6"TQ$
M/4J'Q([>BBBOK3J"O /C1;?8(UTV2SN1;S3"XMKI<>7GG,9[Y&?RQ7O]4=5T
MO3=:T^33]4MH;FVD^]'*,CV/L?<4FKC3L?._PDU"]ADU'0876=9$\^-)1NC0
M]&!YR#G'2N;^)FFZC:ZU:OJN'+HVR-",*H/\(]/\*]5O/@%I<>HM>Z)X@OM/
M8DE5)#E/HP(/YU<TKX'Z1'?)>Z]K%YK,R]IGPI^O))'MFL_9>_SW-O;?N^2Q
MS?@K7;G6_"UA;-;S116D:PR3,1MN-GW<=^,#\JZZ.YEB0*A  .>E=U#X?T2W
MA6&&PMDC0855' I_]C:3_P ^EO\ E7FXG XBM4Y^9+[SCE"4G<X87\HX(7;C
M@#/I2&^G( W 8]![UW7]C:3_ ,^EO^5']C:3_P ^EO\ E6/]F8C^=?B3[.7<
MX7[?.!@%1WZ4PW,C%2P5L*5YSR#7>_V-I/\ SZ6_Y4?V-I/_ #Z6_P"5)Y77
M>\U^(>SEW.%%]..A7@8QBD^V2\GY>3D\'K_D5W?]C:3_ ,^EO^5']C:3_P ^
MEO\ E1_9>(_G7XA[.7<\^DD:60NYRQIM>A_V-I/_ #Z6_P"5']C:3_SZ6_Y5
M+RBL_M+\0]DSSRBO0_[&TG_GTM_RH_L;2?\ GTM_RI?V/5_F7XA[)GGE%>A_
MV-I/_/I;_E1_8VD_\^EO^5']CU?YE^(>R9YX>E>EZ8C)I=HC AA"H(/;BH8]
M)TN*172TMPRG(.!Q6@"",CFN_ X&6';E)WN7"'*%%%%>D:!7"_%3P4_C/PS&
MEJ2-0L9A<6^TX+#HR ]LCI[@5W5!( R3B@<79IGR?>Z3"MNSJES-/$,-;L<L
M3G!(XSD>E)J&AHT5M++E76-4D(&"<C@GUSR.>XKZ(\0>"-&U^4W)+6E[G/VB
M @$GU(Z&N;?X6/)*A.O%47/*0@-SC)Z]??W-8QIRY7%GI5,5056-:BK=X_\
M!['@5]IVH-=PV4"LR7H493YLD#H?3UKV'PQI*^'M#M+&,@O$,LV.K'DG\Z]
MT;P+X?T:,;8%N)L8,LQR?_K5K_V-I/\ SZ6_Y5R8O"5JZ48M)+\SS<0_:/W=
MCA1?3CG*D]B1TI?M\WRD;<@8.><UW/\ 8VD_\^EO^5']C:3_ ,^EO^5<?]F8
MC^=?B<_LY=SA!?3^H/U'3C%*;Z<MG(^F.*[K^QM)_P"?2W_*C^QM)_Y]+?\
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M@ZP#QO&Q\QMKJ58 R,1D'D<&G9J+O_6XKIRT.AHHHJ"PKG_&G_(O#_K]M/\
MTHCKH*Y[QKD>&G<)(XCNK:1A&A<[5G0DX')P 350^)$R^%FMJ(O6M<6#1K-N
M'+C/'?'O68W_  D G=/,AQM9E<J/+ SP&XSG'H:9_P )MH?_ #VO/_!?<?\
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M<G9D@_W<'TYXIJZYIXCYUO4S(!C)L+G!ZYXV]\CZ8XQ1R2[!S1[G13IKS/\
MN9K91Y2]5R-_&[^N/PIJKKPW&26$\L0%P!VQGCIU]#FL*+Q#I\=RLIU?4&42
MA]AT^Y*[><K]W\/P]:C;6],\J1%U:_.\ME6T^ZVX.,# 48QR>,9SS2Y)=@YH
M]SH(H==WF1IXOG.=I(*J#M'&!VY/N?K3]NNBQC&^W:Z\[+GHH3\N>_H>E<TV
MLZ>\(@.LWWE!/+"C3;D97#=<+UY'T"BK=EXHTVVNR9+Z_DA"9^:RN3N<L23R
MIP ,#%')+L'-'N;4=OK'VFU\^=7B1PSLI"Y&TYR .>2,8QTYJKK7_(W>&?\
MKI<_^B32_P#";:'_ ,]KS_P7W'_Q%9\NLV>M>+_#_P!@%S((&N&E9[26-5!B
M(&2R@=:J,9)ZKO\ D)R3V9V-%%%9EA1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7%%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
